These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 21330486)
1. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Yilmaz MI; Sonmez A; Ortiz A; Saglam M; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Çakar M; Egido J; Altun B; Yenicesu M; Blanco-Colio LM; Carrero JJ Clin J Am Soc Nephrol; 2011 Apr; 6(4):785-92. PubMed ID: 21330486 [TBL] [Abstract][Full Text] [Related]
2. Plasma sTWEAK and PTX3: New determinant tools of cardiovascular outcome also in patients with CKD. Meier P Clin J Am Soc Nephrol; 2011 Apr; 6(4):697-9. PubMed ID: 21441127 [No Abstract] [Full Text] [Related]
3. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Yilmaz MI; Carrero JJ; Martín-Ventura JL; Sonmez A; Saglam M; Celik T; Yaman H; Yenicesu M; Eyileten T; Moreno JA; Egido J; Blanco-Colio LM Clin J Am Soc Nephrol; 2010 Jul; 5(7):1174-81. PubMed ID: 20430947 [TBL] [Abstract][Full Text] [Related]
4. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Yilmaz MI; Carrero JJ; Ortiz A; Martín-Ventura JL; Sonmez A; Saglam M; Yaman H; Yenicesu M; Egido J; Blanco-Colio LM Clin J Am Soc Nephrol; 2009 Nov; 4(11):1716-23. PubMed ID: 19820131 [TBL] [Abstract][Full Text] [Related]
5. Serum pentraxin-3 and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) predict severity of infections in acute decompensated cirrhotic patients. Fan WC; Huang CC; Yang YY; Lin A; Lee KC; Hsieh YC; Fung CP; Hsu HC; Hou MC; Lin HC J Microbiol Immunol Infect; 2017 Dec; 50(6):905-914. PubMed ID: 26872435 [TBL] [Abstract][Full Text] [Related]
6. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Yilmaz MI; Stenvinkel P; Sonmez A; Saglam M; Yaman H; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Çakar M; Altun B; Yenicesu M; Carrero JJ Nephrol Dial Transplant; 2011 Nov; 26(11):3537-43. PubMed ID: 21378154 [TBL] [Abstract][Full Text] [Related]
7. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD. Fernández-Laso V; Sastre C; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM Clin J Am Soc Nephrol; 2016 Mar; 11(3):413-22. PubMed ID: 26728587 [TBL] [Abstract][Full Text] [Related]
8. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Yilmaz MI; Sonmez A; Qureshi AR; Saglam M; Stenvinkel P; Yaman H; Eyileten T; Caglar K; Oguz Y; Taslipinar A; Vural A; Gok M; Unal HU; Yenicesu M; Carrero JJ Clin J Am Soc Nephrol; 2011 Jul; 6(7):1617-25. PubMed ID: 21700826 [TBL] [Abstract][Full Text] [Related]